ArticleJournal of inflammation (London, England)2005
Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector.
Article in Journal of inflammation (London, England), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 60 citations in OpenAlex.
- Protective Properties of the White Button Mushroom, Agaricus bisporus, in a Mouse Model of Colitis.Molecular nutrition & food research · 2025Article
- Protective and therapeutic potentials of Trichinella spiralis larval antigen in murine induced colitis.Scientific reports · 2025Article
- Ultrasound-mediated spatial and temporal control of engineered cells in vivo.Nature communications · 2024Article
- Compromised NHE8 Expression Is Responsible for Vitamin D-Deficiency Induced Intestinal Barrier Dysfunction.Nutrients · 2023Article
- Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives.Molecular therapy oncolytics · 2023Review
- FGF21 Depletion Attenuates Colitis through Intestinal Epithelial IL-22-STAT3 Activation in Mice.Nutrients · 2023Article
- High-Density-Immune-Complex Regulatory Macrophages Promote Recovery of Experimental Colitis in Mice.Inflammation · 2021Article
- Article
- The β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion.Brain, behavior, and immunity · 2018Article
- Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes.Nature communications · 2018Article
- The Bisindole Alkaloid Caulerpin, from Seaweeds of the GenusMarine drugs · 2018Article
- COMP-angiopoietin-1 ameliorates inflammation-induced lymphangiogenesis in dextran sulfate sodium (DSS)-induced colitis model.Journal of molecular medicine (Berlin, Germany) · 2018Article
- A Synthetic Mammalian Therapeutic Gene Circuit for Sensing and Suppressing Inflammation.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Targeting the gastrointestinal tract with viral vectors: state of the art and possible applications in research and therapy.Histochemistry and cell biology · 2016Review
- Somatostatin regulates NHE8 protein expression via the ERK1/2 MAPK pathway in DSS-induced colitis mice.American journal of physiology. Gastrointestinal and liver physiology · 2016Article
- The Human Milk Oligosaccharide 2'-Fucosyllactose Quenches Campylobacter jejuni-Induced Inflammation in Human Epithelial Cells HEp-2 and HT-29 and in Mouse Intestinal Mucosa.The Journal of nutrition · 2016Article
- Loss of NHE8 expression impairs intestinal mucosal integrity.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
- T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis.Mucosal immunology · 2015Article
- Allyl isothiocyanate ameliorates angiogenesis and inflammation in dextran sulfate sodium-induced acute colitis.PloS one · 2014Article
- Sepiapterin ameliorates chemically induced murine colitis and azoxymethane-induced colon cancer.The Journal of pharmacology and experimental therapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic deficiency in the expression of interleukin-10 (IL-10) is associated with the onset and progression of experimental inflammatory bowel disease (IBD). The clinical significance of IL-10 expression is supported by studies showing that immune-augmentation of IL-10 prevents inflammation and mucosal damage in animal models of colitis and in human colitis. Interleukin-10 (IL-10), an endogenous anti-inflammatory and immunomodulating cytokine, has been shown to prevent some inflammation and injury in animal and clinical studies, but the efficacy of IL-10 treatment remains unsatisfactory. We found that intra-peritoneal administration of adenoviral IL-10 to mice significantly reversed colitis induced by administration of 3% DSS (dextran sulfate), a common model of colitis. Adenoviral IL-10 (Ad-IL10) transfected mice developed high levels of IL-10 (394 +/- 136 pg/ml) within the peritoneal cavity where the adenovirus was expressed. Importantly, when given on day 4 (after the induction of colitis w/DSS), Ad-IL10 significantly reduced disease activity and weight loss and completely prevented histopathologic injury to the colon at day 10. Mechanistically, compared to Ad-null and DSS treated mice, Ad-IL10 and DSS-treated mice were able to suppress the expression of MAdCAM-1, an endothelial adhesion molecule associated with IBD. Our results suggest that Ad-IL10 (adenoviral IL-10) gene therapy of the intestine or peritoneum may be useful in the clinical treatment of IBD, since we demonstrated that this vector can reverse the course of an existing gut inflammation and markers of inflammation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.